Comparative Pharmacology
Head-to-head clinical analysis: ANUSOL HC versus HC 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANUSOL HC versus HC 4.
ANUSOL HC vs HC #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone, a corticosteroid, binds to glucocorticoid receptors, inhibiting phospholipase A2 activity and reducing prostaglandin and leukotriene synthesis. It also suppresses cytokine production and inflammatory cell migration, leading to decreased edema, erythema, and pruritus in anorectal tissues.
HC #4 is a complex homeopathic preparation with no well-defined molecular mechanism; it is believed to act via hormesis or placebo effects.
Apply a thin layer to the affected area rectally 2 to 4 times daily, or after each bowel movement, for up to 7 days. Each application should not exceed 1 gram.
Hydrocortisone 100-300 mg IV bolus, followed by 100-200 mg IV every 6 hours for 24-48 hours; then taper as clinically indicated.
None Documented
None Documented
Terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours (range 1-3 h) in adults; clinical effect outlasts half-life due to intracellular receptor-mediated action.
Terminal elimination half-life: 12 hours (range 10–14 hours). Extends to 24 hours in severe renal impairment (CrCl <30 mL/min); dose adjustment recommended.
Renal (primarily as metabolites) >80%; fecal ~15%; <2% unchanged in urine due to extensive hepatic metabolism. Biliary excretion is negligible.
Renal excretion of unchanged drug: 95%; fecal/biliary: <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid